Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent single umbilical cord blood transplantation...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2017-08, Vol.52 (8), p.1138-1143 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1143 |
|---|---|
| container_issue | 8 |
| container_start_page | 1138 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 52 |
| creator | Kwon, M Bautista, G Balsalobre, P Sánchez-Ortega, I Montesinos, P Bermúdez, A de Laiglesia, A Herrera, P Martin, C Humala, K Zabalza, A Torres, M Bento, L Corral, L L Heras, I Serrano, D Buño, I Anguita, J Regidor, C Duarte, R Cabrera, R Gayoso, J Diez-Martin, J L |
| description | For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent single umbilical cord blood transplantation supported by a third party donor (Haplo-Cord) between 1999 and 2012, and 36 patients received an haploidentical HSCT with post-transplant cyclophosphamide (PTCY–haplo) between 2012 and 2014 in GETH centers. The Haplo-Cord cohort included a higher proportion of patients with high disease risk index and use of TBI in the conditioning regimen, and hematopoietic cell transplantation–age Comorbidity Age Index was higher in PTCY–haplo patients. Cumulative incidence of neutrophil engraftment was 97% in the Haplo-Cord and 100% in the PTCY–haplo group, achieved in a median of 12 and 17 days, respectively (
P
=0.01). Grade II–IV acute GvHD rate was significantly higher in the PTCY–haplo group (9.8% vs 29%,
P
=0.02) as well as chronic GvHD rates (20% vs 38%,
P
=0.03). With a median follow-up of 61 months for the Haplo-Cord group and 26 months for the PTCY–haplo cohort, overall survival at 2 years was 55% and 59% (
P
=0.66), event-free survival was 45% vs 56% (
P
=0.46), relapse rate was 27% vs 21% (
P
=0.79), and non-relapse mortality was 17% vs 23% (
P
=0.54), respectively. In this multicenter experience, Haplo-Cord and PTCY–haplo HSCT offer valid alternatives for patients with AML. Neutrophil engraftment was faster in the Haplo-Cord cohort, with similar survival rates, with higher GvHD rates after haploidentical HSCT. |
| doi_str_mv | 10.1038/bmt.2017.36 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881770492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A499704710</galeid><sourcerecordid>A499704710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-630bd084651a00147202a1a4adc852a48aefa88ba033d581936855dc295a62b03</originalsourceid><addsrcrecordid>eNp9ks2L1TAUxYMoznN05V4Kggxon_luunw8Rkd44kbX4TZNpxnapiYpMjv_dFPe6MzoIFkEcn_n3NzkIPSS4C3BTL1vxrSlmFRbJh-hDeGVLAWT4jHaYCpVyZisT9CzGK8wJpxj8RSdUMW45ERs0M8LmAdf7n1oixRgivMAU4Lk_FQYP84QbC74ol8x19opOQPDP-gPl_pi9jGVt5XCXJvBz72Pcw9j1hZuKubMZ5N4VOw-H56jJx0M0b642U_Rtw_nX_cX5eHLx0_73aE0glSplAw3LVZcCgLrHBXFFAhwaI0SFLgC24FSDWDGWqFIzaQSojW0FiBpg9kpOjv6zsF_X2xMenTR2CHf1PolaqIUqSrMa5rR13-hV34JU76dppJTKlmF6_9RpKZi9RP4lrqEwWo3dT4_kFlb6x2v69ywIiu1fYDKq7WjM36yncvn9wRv7gh6C0Pqox-W9TPiffDtETTBxxhsp-fgRgjXmmC9xkfn-Og1PprJTL-6mWlpRtv-YX_nJQPvjkDMpenShjtDP-D3C-vGzUY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925188150</pqid></control><display><type>article</type><title>Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML</title><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kwon, M ; Bautista, G ; Balsalobre, P ; Sánchez-Ortega, I ; Montesinos, P ; Bermúdez, A ; de Laiglesia, A ; Herrera, P ; Martin, C ; Humala, K ; Zabalza, A ; Torres, M ; Bento, L ; Corral, L L ; Heras, I ; Serrano, D ; Buño, I ; Anguita, J ; Regidor, C ; Duarte, R ; Cabrera, R ; Gayoso, J ; Diez-Martin, J L</creator><creatorcontrib>Kwon, M ; Bautista, G ; Balsalobre, P ; Sánchez-Ortega, I ; Montesinos, P ; Bermúdez, A ; de Laiglesia, A ; Herrera, P ; Martin, C ; Humala, K ; Zabalza, A ; Torres, M ; Bento, L ; Corral, L L ; Heras, I ; Serrano, D ; Buño, I ; Anguita, J ; Regidor, C ; Duarte, R ; Cabrera, R ; Gayoso, J ; Diez-Martin, J L ; on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)</creatorcontrib><description>For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent single umbilical cord blood transplantation supported by a third party donor (Haplo-Cord) between 1999 and 2012, and 36 patients received an haploidentical HSCT with post-transplant cyclophosphamide (PTCY–haplo) between 2012 and 2014 in GETH centers. The Haplo-Cord cohort included a higher proportion of patients with high disease risk index and use of TBI in the conditioning regimen, and hematopoietic cell transplantation–age Comorbidity Age Index was higher in PTCY–haplo patients. Cumulative incidence of neutrophil engraftment was 97% in the Haplo-Cord and 100% in the PTCY–haplo group, achieved in a median of 12 and 17 days, respectively (
P
=0.01). Grade II–IV acute GvHD rate was significantly higher in the PTCY–haplo group (9.8% vs 29%,
P
=0.02) as well as chronic GvHD rates (20% vs 38%,
P
=0.03). With a median follow-up of 61 months for the Haplo-Cord group and 26 months for the PTCY–haplo cohort, overall survival at 2 years was 55% and 59% (
P
=0.66), event-free survival was 45% vs 56% (
P
=0.46), relapse rate was 27% vs 21% (
P
=0.79), and non-relapse mortality was 17% vs 23% (
P
=0.54), respectively. In this multicenter experience, Haplo-Cord and PTCY–haplo HSCT offer valid alternatives for patients with AML. Neutrophil engraftment was faster in the Haplo-Cord cohort, with similar survival rates, with higher GvHD rates after haploidentical HSCT.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2017.36</identifier><identifier>PMID: 28346415</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/2171 ; 692/699/1541/1990/283/1897 ; Acute myelocytic leukemia ; Blood ; Bone marrow ; Care and treatment ; Cell Biology ; Cord blood ; Cyclophosphamide ; Dosage and administration ; Fetal blood ; Graft-versus-host reaction ; Health risks ; Hematology ; Hematopoietic stem cell transplantation ; Incidence ; Internal Medicine ; Leukocytes (neutrophilic) ; Medicine ; Medicine & Public Health ; Neutrophils ; original-article ; Patients ; Public Health ; Stem cell transplantation ; Stem Cells ; Survival ; Transplantation ; Transplants & implants ; Umbilical cord</subject><ispartof>Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1138-1143</ispartof><rights>Macmillan Publishers Limited, part of Springer Nature. 2017</rights><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Aug 2017</rights><rights>Macmillan Publishers Limited, part of Springer Nature. 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-630bd084651a00147202a1a4adc852a48aefa88ba033d581936855dc295a62b03</citedby><cites>FETCH-LOGICAL-c517t-630bd084651a00147202a1a4adc852a48aefa88ba033d581936855dc295a62b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2017.36$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2017.36$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28346415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, M</creatorcontrib><creatorcontrib>Bautista, G</creatorcontrib><creatorcontrib>Balsalobre, P</creatorcontrib><creatorcontrib>Sánchez-Ortega, I</creatorcontrib><creatorcontrib>Montesinos, P</creatorcontrib><creatorcontrib>Bermúdez, A</creatorcontrib><creatorcontrib>de Laiglesia, A</creatorcontrib><creatorcontrib>Herrera, P</creatorcontrib><creatorcontrib>Martin, C</creatorcontrib><creatorcontrib>Humala, K</creatorcontrib><creatorcontrib>Zabalza, A</creatorcontrib><creatorcontrib>Torres, M</creatorcontrib><creatorcontrib>Bento, L</creatorcontrib><creatorcontrib>Corral, L L</creatorcontrib><creatorcontrib>Heras, I</creatorcontrib><creatorcontrib>Serrano, D</creatorcontrib><creatorcontrib>Buño, I</creatorcontrib><creatorcontrib>Anguita, J</creatorcontrib><creatorcontrib>Regidor, C</creatorcontrib><creatorcontrib>Duarte, R</creatorcontrib><creatorcontrib>Cabrera, R</creatorcontrib><creatorcontrib>Gayoso, J</creatorcontrib><creatorcontrib>Diez-Martin, J L</creatorcontrib><creatorcontrib>on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)</creatorcontrib><title>Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent single umbilical cord blood transplantation supported by a third party donor (Haplo-Cord) between 1999 and 2012, and 36 patients received an haploidentical HSCT with post-transplant cyclophosphamide (PTCY–haplo) between 2012 and 2014 in GETH centers. The Haplo-Cord cohort included a higher proportion of patients with high disease risk index and use of TBI in the conditioning regimen, and hematopoietic cell transplantation–age Comorbidity Age Index was higher in PTCY–haplo patients. Cumulative incidence of neutrophil engraftment was 97% in the Haplo-Cord and 100% in the PTCY–haplo group, achieved in a median of 12 and 17 days, respectively (
P
=0.01). Grade II–IV acute GvHD rate was significantly higher in the PTCY–haplo group (9.8% vs 29%,
P
=0.02) as well as chronic GvHD rates (20% vs 38%,
P
=0.03). With a median follow-up of 61 months for the Haplo-Cord group and 26 months for the PTCY–haplo cohort, overall survival at 2 years was 55% and 59% (
P
=0.66), event-free survival was 45% vs 56% (
P
=0.46), relapse rate was 27% vs 21% (
P
=0.79), and non-relapse mortality was 17% vs 23% (
P
=0.54), respectively. In this multicenter experience, Haplo-Cord and PTCY–haplo HSCT offer valid alternatives for patients with AML. Neutrophil engraftment was faster in the Haplo-Cord cohort, with similar survival rates, with higher GvHD rates after haploidentical HSCT.</description><subject>692/308/2171</subject><subject>692/699/1541/1990/283/1897</subject><subject>Acute myelocytic leukemia</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Cord blood</subject><subject>Cyclophosphamide</subject><subject>Dosage and administration</subject><subject>Fetal blood</subject><subject>Graft-versus-host reaction</subject><subject>Health risks</subject><subject>Hematology</subject><subject>Hematopoietic stem cell transplantation</subject><subject>Incidence</subject><subject>Internal Medicine</subject><subject>Leukocytes (neutrophilic)</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neutrophils</subject><subject>original-article</subject><subject>Patients</subject><subject>Public Health</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Umbilical cord</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9ks2L1TAUxYMoznN05V4Kggxon_luunw8Rkd44kbX4TZNpxnapiYpMjv_dFPe6MzoIFkEcn_n3NzkIPSS4C3BTL1vxrSlmFRbJh-hDeGVLAWT4jHaYCpVyZisT9CzGK8wJpxj8RSdUMW45ERs0M8LmAdf7n1oixRgivMAU4Lk_FQYP84QbC74ol8x19opOQPDP-gPl_pi9jGVt5XCXJvBz72Pcw9j1hZuKubMZ5N4VOw-H56jJx0M0b642U_Rtw_nX_cX5eHLx0_73aE0glSplAw3LVZcCgLrHBXFFAhwaI0SFLgC24FSDWDGWqFIzaQSojW0FiBpg9kpOjv6zsF_X2xMenTR2CHf1PolaqIUqSrMa5rR13-hV34JU76dppJTKlmF6_9RpKZi9RP4lrqEwWo3dT4_kFlb6x2v69ywIiu1fYDKq7WjM36yncvn9wRv7gh6C0Pqox-W9TPiffDtETTBxxhsp-fgRgjXmmC9xkfn-Og1PprJTL-6mWlpRtv-YX_nJQPvjkDMpenShjtDP-D3C-vGzUY</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Kwon, M</creator><creator>Bautista, G</creator><creator>Balsalobre, P</creator><creator>Sánchez-Ortega, I</creator><creator>Montesinos, P</creator><creator>Bermúdez, A</creator><creator>de Laiglesia, A</creator><creator>Herrera, P</creator><creator>Martin, C</creator><creator>Humala, K</creator><creator>Zabalza, A</creator><creator>Torres, M</creator><creator>Bento, L</creator><creator>Corral, L L</creator><creator>Heras, I</creator><creator>Serrano, D</creator><creator>Buño, I</creator><creator>Anguita, J</creator><creator>Regidor, C</creator><creator>Duarte, R</creator><creator>Cabrera, R</creator><creator>Gayoso, J</creator><creator>Diez-Martin, J L</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170801</creationdate><title>Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML</title><author>Kwon, M ; Bautista, G ; Balsalobre, P ; Sánchez-Ortega, I ; Montesinos, P ; Bermúdez, A ; de Laiglesia, A ; Herrera, P ; Martin, C ; Humala, K ; Zabalza, A ; Torres, M ; Bento, L ; Corral, L L ; Heras, I ; Serrano, D ; Buño, I ; Anguita, J ; Regidor, C ; Duarte, R ; Cabrera, R ; Gayoso, J ; Diez-Martin, J L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-630bd084651a00147202a1a4adc852a48aefa88ba033d581936855dc295a62b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>692/308/2171</topic><topic>692/699/1541/1990/283/1897</topic><topic>Acute myelocytic leukemia</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Cord blood</topic><topic>Cyclophosphamide</topic><topic>Dosage and administration</topic><topic>Fetal blood</topic><topic>Graft-versus-host reaction</topic><topic>Health risks</topic><topic>Hematology</topic><topic>Hematopoietic stem cell transplantation</topic><topic>Incidence</topic><topic>Internal Medicine</topic><topic>Leukocytes (neutrophilic)</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neutrophils</topic><topic>original-article</topic><topic>Patients</topic><topic>Public Health</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Umbilical cord</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, M</creatorcontrib><creatorcontrib>Bautista, G</creatorcontrib><creatorcontrib>Balsalobre, P</creatorcontrib><creatorcontrib>Sánchez-Ortega, I</creatorcontrib><creatorcontrib>Montesinos, P</creatorcontrib><creatorcontrib>Bermúdez, A</creatorcontrib><creatorcontrib>de Laiglesia, A</creatorcontrib><creatorcontrib>Herrera, P</creatorcontrib><creatorcontrib>Martin, C</creatorcontrib><creatorcontrib>Humala, K</creatorcontrib><creatorcontrib>Zabalza, A</creatorcontrib><creatorcontrib>Torres, M</creatorcontrib><creatorcontrib>Bento, L</creatorcontrib><creatorcontrib>Corral, L L</creatorcontrib><creatorcontrib>Heras, I</creatorcontrib><creatorcontrib>Serrano, D</creatorcontrib><creatorcontrib>Buño, I</creatorcontrib><creatorcontrib>Anguita, J</creatorcontrib><creatorcontrib>Regidor, C</creatorcontrib><creatorcontrib>Duarte, R</creatorcontrib><creatorcontrib>Cabrera, R</creatorcontrib><creatorcontrib>Gayoso, J</creatorcontrib><creatorcontrib>Diez-Martin, J L</creatorcontrib><creatorcontrib>on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, M</au><au>Bautista, G</au><au>Balsalobre, P</au><au>Sánchez-Ortega, I</au><au>Montesinos, P</au><au>Bermúdez, A</au><au>de Laiglesia, A</au><au>Herrera, P</au><au>Martin, C</au><au>Humala, K</au><au>Zabalza, A</au><au>Torres, M</au><au>Bento, L</au><au>Corral, L L</au><au>Heras, I</au><au>Serrano, D</au><au>Buño, I</au><au>Anguita, J</au><au>Regidor, C</au><au>Duarte, R</au><au>Cabrera, R</au><au>Gayoso, J</au><au>Diez-Martin, J L</au><aucorp>on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>52</volume><issue>8</issue><spage>1138</spage><epage>1143</epage><pages>1138-1143</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent single umbilical cord blood transplantation supported by a third party donor (Haplo-Cord) between 1999 and 2012, and 36 patients received an haploidentical HSCT with post-transplant cyclophosphamide (PTCY–haplo) between 2012 and 2014 in GETH centers. The Haplo-Cord cohort included a higher proportion of patients with high disease risk index and use of TBI in the conditioning regimen, and hematopoietic cell transplantation–age Comorbidity Age Index was higher in PTCY–haplo patients. Cumulative incidence of neutrophil engraftment was 97% in the Haplo-Cord and 100% in the PTCY–haplo group, achieved in a median of 12 and 17 days, respectively (
P
=0.01). Grade II–IV acute GvHD rate was significantly higher in the PTCY–haplo group (9.8% vs 29%,
P
=0.02) as well as chronic GvHD rates (20% vs 38%,
P
=0.03). With a median follow-up of 61 months for the Haplo-Cord group and 26 months for the PTCY–haplo cohort, overall survival at 2 years was 55% and 59% (
P
=0.66), event-free survival was 45% vs 56% (
P
=0.46), relapse rate was 27% vs 21% (
P
=0.79), and non-relapse mortality was 17% vs 23% (
P
=0.54), respectively. In this multicenter experience, Haplo-Cord and PTCY–haplo HSCT offer valid alternatives for patients with AML. Neutrophil engraftment was faster in the Haplo-Cord cohort, with similar survival rates, with higher GvHD rates after haploidentical HSCT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28346415</pmid><doi>10.1038/bmt.2017.36</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1138-1143 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1881770492 |
| source | SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 692/308/2171 692/699/1541/1990/283/1897 Acute myelocytic leukemia Blood Bone marrow Care and treatment Cell Biology Cord blood Cyclophosphamide Dosage and administration Fetal blood Graft-versus-host reaction Health risks Hematology Hematopoietic stem cell transplantation Incidence Internal Medicine Leukocytes (neutrophilic) Medicine Medicine & Public Health Neutrophils original-article Patients Public Health Stem cell transplantation Stem Cells Survival Transplantation Transplants & implants Umbilical cord |
| title | Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A08%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haplo-Cord%20transplantation%20compared%20to%20haploidentical%20transplantation%20with%20post-transplant%20cyclophosphamide%20in%20patients%20with%20AML&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Kwon,%20M&rft.aucorp=on%20behalf%20of%20Grupo%20Espa%C3%B1ol%20de%20Trasplante%20Hematopoy%C3%A9tico%20y%20Terapia%20Celular%20(GETH)&rft.date=2017-08-01&rft.volume=52&rft.issue=8&rft.spage=1138&rft.epage=1143&rft.pages=1138-1143&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2017.36&rft_dat=%3Cgale_proqu%3EA499704710%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925188150&rft_id=info:pmid/28346415&rft_galeid=A499704710&rfr_iscdi=true |